R. Gray

发表

Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study

D. Kerr, R. Gray, J. Barnwell, 2007, The Lancet.

Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials

R Peto, R. Peto, T. Whelan, 2011, The Lancet.

Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials

R. Collins, R. Peto, S. Darby, 2005, The Lancet.

Intratumoral stromal morphometry predicts disease recurrence but not response to 5‐fluorouracil—results from the QUASAR trial of colorectal cancer

D. Treanor, D. Kerr, R. Gray, 2018, Histopathology.

Tamoxifen in breast conservation therapy.

R. Gray, K. S. Lee, P. Plowman, 1995, International journal of clinical pharmacology and therapeutics.

Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukaemia: results of the United Kingdom Medical Research Council's 10th AML trial

R. Gray, K. Wheatley, R. Stevens, 1998 .

Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials

Mike Clarke, R. Collins, R. Peto, 2000 .

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

Ming-Feng Hou, Antonella Delmestri, Rodrigo Arriagada, 2013, The Lancet.

20‐Year Risks of Breast‐Cancer Recurrence after Stopping Endocrine Therapy at 5 Years

Daniel F. Hayes, Mitch Dowsett, Jonas Bergh, 2017, The New England journal of medicine.

Estimating the Risks of Breast Cancer Radiotherapy: Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous Randomized Trials.

J. Bergh, R. Peto, R. Jagsi, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials

R. Peto, T. Whelan, S. Darby, 2014, The Lancet.

Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials

J. Cuzick, J. Bergh, R. Peto, 2022, The Lancet. Oncology.

Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials

E. Rutgers, E. Winer, J. Cuzick, 2015, The Lancet.

QUASAR: a UKCCCR study of adjuvant chemotherapy (CT) for colorectal cancer

D. Kerr, R. Gray, C. McConkey, 1999 .

Predictors of recurrence during years 5-14 in 46,138 women with ER+ breast cancer allocated 5 years only of endocrine therapy (ET).

J. Bergh, R. Peto, M. Dowsett, 2016 .

Can we Save the rectum by watchful waiting or TransAnal microsurgery following (chemo) Radiotherapy versus Total mesorectal excision for early REctal Cancer (STAR-TREC study)?: protocol for a multicentre, randomised feasibility study

I. Nagtegaal, R. Gray, C. Punt, 2017, BMJ Open.

FOxTROT: Randomized phase II study of neoadjuvant chemotherapy (CT) with or without an anti-EGFR monoclonal antibody for locally advanced, operable colon cancer: Planned interim report.

R. Gray, B. Warren, P. Quirke, 2011, Journal of Clinical Oncology.

Adjuvant therapy for cancer of the colon.

R. Gray, M. Slevin, 1991, BMJ.

Portal vein chemotherapy for colorectal cancer: a meta-analysis of 4000 patients in 10 studies. Liver Infusion Meta-analysis Group.

R. Peto, M. Buyse, R. Gray, 1997, Journal of the National Cancer Institute.

Comparison of molecular and pathologic features of stage II and stage III colon cancer in four large studies conducted for development of the 12-gene colon cancer recurrence score.

D. Kerr, N. Wolmark, R. Gray, 2010 .

Chemotherapy versus transplants for acute myelogenous leukemia in second remission.

J. Klein, M. Oken, R. Gray, 1996, Leukemia.

Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council's 10th AML trial. MRC Childhood Leukaemia Working Party.

R. Gray, K. Wheatley, R. Stevens, 1998, British journal of haematology.

Severe adverse impact on sexual functioning and fertility of bone marrow transplantation, either allogeneic or autologous, compared with consolidation chemotherapy alone

R. Gray, R. Zittoun, A. Burnett, 1999, Cancer.

AML in Children: The Medical Research Council Data

R. Gray, K. Wheatley, R. Stevens, 2001 .

Abstract GS4-02: Regional lymph node irradiation in early stage breast cancer: An EBCTCG meta-analysis of 13,000 women in 14 trials

T. Whelan, T. Kühn, R. Gray, 2019, General Session Abstracts.

Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials

Mike Clarke, Yasuo Ohashi, Michael Gnant, 2018, The Lancet. Oncology.

Neoadjuvant chemotherapy for early breast cancer - Author's reply.

R. Gray, P. Mcgale, D. Dodwell, 2018, The Lancet. Oncology.

Chemotherapeutic Options in Chronic Lymphocytic Leukemia: a Meta-analysis of the Randomized Trials

E. Kimby, F. Bosch, E. Montserrat, 1999 .

Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials: Chronic Myeloid Leukemia Trialists' Collaborative Group.

H. Heimpel, R. Peto, J. Hasford, 1997, Journal of the National Cancer Institute.

A phase II trial of neoadjuvant MK2206, an AKT inhibitor, with anastrozole in clinical stage 2 or 3 PIK3CA mutant ER positive and HER2 negative breast cancer Estrogen receptor positive breast cancer, neoadjuvant endocrine therapy,

Erica K. Barnell, E. Mardis, O. Griffith, 2017 .

QUASAR: A randomized study of adjuvant chemotherapy (CT) vs observation including 3238 colorectal cancer patients.

D. Kerr, R. Gray, J. Barnwell, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Autografting for patients with CML in chronic phase: an update

R. Gray, J. Goldman, C. Hoyle, 1994, British journal of haematology.

Prognostic and Predictive Value of Tumor Budding in Colorectal Cancer.

R. Gray, P. Quirke, R. Riddell, 2021, Clinical colorectal cancer.

Patient-level meta-analysis of randomized trials of aromatase inhibitors (AI) versus tamoxifen (Tam).

J. Cuzick, J. Forbes, M. Dowsett, 2014 .

aTTom (adjuvant Tamoxifen--To offer more?): Randomized trial of 10 versus 5 years of adjuvant tamoxifen among 6,934 women with estrogen receptor-positive (ER+) or ER untested breast cancer--Preliminary results

H. Earl, R. Gray, C. Poole, 2008 .

Estrogen-receptor-directed neoadjuvant therapy for breast cancer: results of a randomised trial using formestane and methotrexate, mitozantrone and mitomycin C (MMM) chemotherapy.

R. Gray, C. McConkey, J. Gazet, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Tamoxifen for early breast cancer: better late than never.

R. Gray, C. Davies, P. Perry, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials.

R. Peto, M. Piccart, S. Darby, 2012, Lancet.

Allo and auto BMT reduce relapse risk in AML in CR1 but do not significantly improve overall survival Results of the MRC AML 10 trial

R. Gray, A. Burnett, K. Wheatley, 1996 .

A simple, robust and highly predictive prognostic index for the determination of risk directed therapy in acute myeloid leukaemia (AML) derived from the United Kingdom medical research council (MRC) AML10 trial.

R. Gray, A. Burnett, K. Wheatley, 1995 .

Dose intensification in acute myloid leukaemia: greater effectiveness at lower cost. Principal report of the Medical Research Council's ATML9 study

R. Gray, K. Wheatley, J. Rees, 1996, British journal of haematology.

Prognostic importance of Sudan Black positivity: a study of bone marrow slides from 1386 patients with de novo acute myeloid leukaemia

R. Gray, P. Sherrington, D. Swirsky, 1991, British journal of haematology.

The ninth British Medical Research Council trial for the treatment of acute myeloid leukaemia.

R. Gray, F. Hayhoe, J. Rees, 1987, Haematology and blood transfusion.

Anal fistula plug versus surgeon's preference for surgery for trans-sphincteric anal fistula: the FIAT RCT.

R. Gray, D. Jayne, J. Scholefield, 2019, Health technology assessment.

5'fluorouracil (FU) and folinic acid (FA) in either the weekly 'Roswell Park' or the 4-weekly 'Mayo' regimen should be standard chemotherapy for colon cancer.

R. Gray, 2003, European journal of cancer.

Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial

Keith Wheatley, R. Gray, A. Goldstone, 1998, The Lancet.

Tobacco smoking and the risk of Parkinson disease

R. Peto, R. Gray, R. Clarke, 2020, Neurology.

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

R Peto, R. Peto, M. Dowsett, 2011, The Lancet.

PRINCIPAL RESULTS OF THE MEDICAL RESEARCH COUNCIL'S 8th ACUTE MYELOID LEUKAEMIA TRIAL

R. Gray, D. Swirsky, F. Hayhoe, 1986, The Lancet.

Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials

Bingshu E. Chen, D. Berry, P. Fasching, 2019, The Lancet.

Sequential biochemical modulation of fluorouracil with folinic acid, N-phosphonacetyl-L-aspartic acid, and interferon alfa-2a in advanced colorectal cancer.

R. Gray, R. Winn, R. Pazdur, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sequential B iochemical M odulation o f F luorouracil W ith Folinic A cid, N -Phosphonacetyl -L-Aspartic A cid, a nd Interferon A lfa-2a i n A dvanced C olorectal C ancer

R. Gray, R. Winn, R. Pazdur, 1999 .

Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women

Mike Clarke, R. Collins, R. Peto, 1992 .

Long-term follow-up of a randomised trial designed to determine the need for irradiation following conservative surgery for the treatment of invasive breast cancer.

R. Coombes, R. Gray, C. McConkey, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

EFFECTS OF RADIOTHERAPY AND SURGERY IN EARLY BREAST-CANCER - AN OVERVIEW OF THE RANDOMIZED TRIALS

Mike Clarke, R. Collins, R. Peto, 1995 .

Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease: a meta-analysis of 23 randomized trials involving 3,888 patients. International Hodgkin's Disease Collaborative Group.

R Peto, R. Peto, R. Gray, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Terminal deoxynucleotidyl transferase and HLA‐DR expression appear unrelated to prognosis of acute myeloid leukaemia

M. Greaves, R. Gray, D. Swirsky, 1988, British journal of haematology.

Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer.

D. Kerr, S. Shak, F. Baehner, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A simple, robust, validated and highly predictive index for the determination of risk‐directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial

R. Gray, A. Goldstone, A. Burnett, 1999, British journal of haematology.

AML associated with previous cytotoxic therapy, MDS or myeloproliferative disorders: results from the MRC's 9th AML trial

R. Gray, P. Sherrington, K. Wheatley, 1989, British journal of haematology.

Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer.

D. Kerr, R. Gray, P. Quirke, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group.

Mike Clarke, K Wheatley, A Riccardi, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials.

R. Peto, S. Darby, A. Goldhirsch, 2008, Lancet.

HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials

J. Barrett, D. Kerr, R. Gray, 2016, The Journal of pathology.

Partial ablation versus radical prostatectomy in intermediate-risk prostate cancer: the PART feasibility RCT.

F. Hamdy, J. Donovan, R. Fitzpatrick, 2018, Health technology assessment.

Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials.

Daniel J Sargent, Daniel G Haller, Marc Buyse, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council's 10th AML trial (MRC AML10). Adult and Childhood Leukaemia Working Parties of the Medical Research Council.

R. Gray, R. Gray, A. Goldstone, 1997, Blood.

Comparison of 1 + 5 DAT and 3 + 10 DAT followed by COAP or MAZE consolidation therapy in the treatment of acute myeloid leukemia: MRC ninth AML trial.

R. Gray, J. Rees, 1987, Seminars in oncology.

Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials

J. Cuzick, J. Bergh, R. Peto, 2021, The Lancet. Oncology.

A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia

R. Peto, F. Mandelli, R. Gray, 1998, British journal of haematology.

Systematic review and meta‐analysis of randomized clinical trials of self‐expanding metallic stents as a bridge to surgery versus emergency surgery for malignant left‐sided large bowel obstruction (Br J Surg 2012; 99: 469–476)

R. Gray, D. Jayne, D. Morton, 2012, The British journal of surgery.

CREST: Randomised phase III study of stenting as a bridge to surgery in obstructing colorectal cancer--Results of the UK ColoRectal Endoscopic Stenting Trial (CREST).

R. Gray, D. Morton, K. Handley, 2016 .

Clinical-grade Detection of Microsatellite Instability in Colorectal Tumors by Deep Learning.

Alexander T. Pearson, Philip Quirke, Jakob Nikolas Kather, 2020, Gastroenterology.

The effect of diuretic pre-treatment on clinical, morphological and ultrastructural cis-platinum induced nephrotoxicity.

R. Gray, Y. Daskal, A. Winston, 1979, International journal of radiation oncology, biology, physics.

Impact of diagnostic cytogenetics on outcome in AML: Analysis of 1,613 patients entered into the UK MRC AML 10 trial.

R. Gray, D. Grimwade, C. Harrison, 1996 .

Increasing the dose density of adjuvant chemotherapy by shortening intervals between courses or by sequential drug administration significantly reduces both disease recurrence and breast cancer mortality: An EBCTCG meta-analysis of 21,000 women in 16 randomised trials

J. Bergh, R. Peto, L. Norton, 2018 .

Large-scale randomized evidence: trials and overviews.

K Wheatley, R. Collins, R. Peto, 2008 .

A quantitative multigene RT-PCR assay for prediction of recurrence in stage II colon cancer: Selection of the genes in four large studies and results of the independent, prospectively designed QUASAR validation study.

D. Kerr, S. Shak, D. Watson, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group.

Daniel J Sargent, Greg Yothers, Daniel G Haller, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Innovative estimation of survival using log-normal survival modelling on ACCENT database

D. Sargent, P. Catalano, R. Gray, 2013, British Journal of Cancer.

A Multicenter Randomized Controlled Trial Comparing Safety, Efficacy, and Cost-effectiveness of the Surgisis Anal Fistula Plug Versus Surgeon's Preference for Transsphincteric Fistula-in-Ano

R. Gray, D. Jayne, J. Scholefield, 2020, Annals of surgery.

Adjuvant chemotherapy with 5-fluorouracil, L-folinic acid and levamisole for patients with colorectal cancer: non-randomised comparison of weekly versus four-weekly schedules--less pain, same gain. QUASAR Colorectal Cancer Study Group.

D. Kerr, R. Gray, J. Barnwell, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Accuracy of radiological staging in identifying high‐risk colon cancer patients suitable for neoadjuvant chemotherapy: a multicentre experience

R. Gray, B. Warren, P. Quirke, 2012, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

THE PART TRIAL ‐ A PHASE III STUDY COMPARING PARTIAL PROSTATE ABLATION VERSUS RADICAL PROSTATECTOMY (PART) IN INTERMEDIATE RISK PROSTATE CANCER – EARLY DATA FROM THE FEASIBILITY STUDY: PD56‐08

F. Hamdy, J. Donovan, H. Ahmed, 2017 .

Preoperative Chemotherapy for Operable Colon Cancer: Mature Results of an International Randomized Controlled Trial

S. Laurberg, R. Gray, P. Quirke, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tamoxifen does not reduce the risk of lung cancer in women

R. Gray, J. Schiller, J. Patel, 2005 .

Abstract GS3-03: Effects of prolonging adjuvant aromatase inhibitor therapy beyond five years on recurrence and cause-specific mortality: An EBCTCG meta-analysis of individual patient data from 12 randomised trials including 24,912 women

R. Gray, 2019, General Session Abstracts.

Phase II study of CI-980 (NSC 635370) in patients with previously treated advanced soft-tissue sarcomas

R. Gray, R. Benjamin, Shreyaskumar R Patel, 1998, Investigational New Drugs.

FIAT Trial Management Group

R. Gray, D. Jayne, J. Scholefield, 2014 .

Overall and subgroup findings of the aTTom trial: A randomised comparison of continuing adjuvant tamoxifen to 10 years compared to stopping after 5 years in 6953 women with ER positive or ER untested early breast cancer

H. Earl, D. Rea, R. Gray, 2013 .

Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials

S. Steinberg, E. Rutgers, E. Winer, 2018, The Lancet. Oncology.

Comparison of innovative estimation of efficacy to standard using the ACCENT database.

D. Sargent, P. Catalano, R. Gray, 2011, Journal of Clinical Oncology.

Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel.

R. Gray, T. Powles, C. Wilson, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Do tumor infiltrating lymphocytes (TILs) predict benefits from trastuzumab therapy for HER2 positive breast cancer? Meta-analysis of individual patient data from 4097 women in 5 trials.

J. Bergh, M. Dowsett, R. Gelber, 2023, Journal of Clinical Oncology.